Literature DB >> 25620781

Determination of MICING: a new assay for assessing minimal inhibitory concentration for invasive growth.

J Zupan1, Z Tomičić, P Raspor.   

Abstract

Our work was focused on a new assay for characterising clinically important yeast. This assay was developed due to the need for new diagnostic methods for recognising potentially virulent strains of increasingly important non-albicans yeast pathogens, such as Saccharomyces cerevisiae and Candida glabrata. With the great diversity among strains for virulence and virulence factors, identification to the species level is not sufficient; therefore, testing for specific virulent traits remains the best option. We show here that the proposed assay uncovers the relationships between the three most important yeast virulence traits in a single test: the ability of a strain to invade solid medium, while resisting the presence of an antimycotic and high temperature (37 °C). We combined the quantitative agar invasion assay with classical antimycotic susceptibility testing into a single assay. Similarly to the minimal inhibitory concentration (MIC) value, we defined the MICING (minimal inhibitory concentration of antimycotic for invasive growth) as the concentration of an antimycotic above which the yeast invasive growth is significantly repressed. In this study, we tested three of the most common antimycotics: fluconazole, itraconazole and amphotericin B. The response of yeast strains invasion was characteristic of each antimycotic, indicating their mechanisms of action. In addition to MICING, the assay provides quantitative information about the superficial and invasive growth, and also about the relative invasion, which helps in identifying clinically important yeast, such as azole-resistant and/or invasive strains of S. cerevisiae and C. glabrata.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25620781     DOI: 10.1007/s10096-015-2324-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  34 in total

1.  Efflux-mediated resistance to fluconazole could be modulated by sterol homeostasis in Saccharomyces cerevisiae.

Authors:  D P Kontoyiannis
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

Review 2.  Fungal morphogenesis and host invasion.

Authors:  Neil A R Gow; Alistair J P Brown; Frank C Odds
Journal:  Curr Opin Microbiol       Date:  2002-08       Impact factor: 7.934

3.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

4.  Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome.

Authors:  V Krcmery; E Oravcova; S Spanik; M Mrazova-Studena; J Trupl; A Kunova; K Stopkova-Grey; E Kukuckova; I Krupova; A Demitrovicova; K Kralovicova
Journal:  J Antimicrob Chemother       Date:  1998-03       Impact factor: 5.790

5.  Are live saccharomyces yeasts harmful to patients?

Authors:  R Piarroux; L Millon; K Bardonnet; O Vagner; H Koenig
Journal:  Lancet       Date:  1999-05-29       Impact factor: 79.321

6.  A Saccharomyces cerevisiae mutant with increased virulence.

Authors:  Robert T Wheeler; Martin Kupiec; Paula Magnelli; Claudia Abeijon; Gerald R Fink
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-14       Impact factor: 11.205

7.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

8.  Seven cases of fungemia with Saccharomyces boulardii in critically ill patients.

Authors:  Thierry Lherm; Claire Monet; Bruno Nougière; Muriel Soulier; Daho Larbi; Christian Le Gall; Daniel Caen; Claire Malbrunot
Journal:  Intensive Care Med       Date:  2002-05-10       Impact factor: 17.440

9.  Quantitative agar-invasion assay.

Authors:  Jure Zupan; Peter Raspor
Journal:  J Microbiol Methods       Date:  2008-03-10       Impact factor: 2.363

Review 10.  Outbreak of Saccharomyces cerevisiae subtype boulardii fungemia in patients neighboring those treated with a probiotic preparation of the organism.

Authors:  Marco Cassone; Pietro Serra; Francesca Mondello; Antonietta Girolamo; Sandro Scafetti; Eleonora Pistella; Mario Venditti
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.